4.7 Article

Gremlin is a novel agonist of the major proangiogenic receptor VEGFR2

期刊

BLOOD
卷 116, 期 18, 页码 3677-3680

出版社

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2010-06-291930

关键词

-

资金

  1. Istituto Superiore di Sanita
  2. Ministero dell'Istruzione
  3. Universita e Ricerca (Centro di Eccellenza per l'Innovazione Diagnostica e Terapeutica)
  4. Associazione Italiana per la Ricerca sul Cancro (AIRC) [MFAG 9161]
  5. Fondazione Berlucchi
  6. Fondazione Cariplo [2008-2264]
  7. Swiss National Science Foundation [3100A-116507]
  8. Oncosuisse [OC2 01200-08-2007]

向作者/读者索取更多资源

The bone morphogenic protein antagonist gremlin is expressed during embryonic development and under different pathologic conditions, including cancer. Gremlin is a proangiogenic protein belonging to the cystine-knot superfamily that includes transforming growth factor-beta proteins and the angiogenic vascular endothelial growth factors (VEGFs). Here, we demonstrate that gremlin binds VEGF receptor-2 (VEGFR2), the main transducer of VEGF-mediated angiogenic signals, in a bone morphogenic protein-independent manner. Similar to VEGF-A, gremlin activates VEGFR2 in endothelial cells, leading to VEGFR2-dependent angiogenic responses in vitro and in vivo. Gremlin thus represents a novel proangiogenic VEGFR2 agonist distinct from the VEGF family ligands with implications in vascular development, angiogenesis-dependent diseases, and tumor neovascularization. (Blood. 2010;116(18):3677-3680)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据